Valuation: Exelixis, Inc.

Market Cap 16.84B 15.26B 14.11B 12.73B 24B 1,588B 24.84B 170B 67.22B 848B 63.18B 61.84B 2,692B P/E 2026 *
20.1x
P/E 2027 * 17x
Enterprise Value 15.89B 14.4B 13.32B 12.02B 22.65B 1,499B 23.45B 160B 63.45B 801B 59.64B 58.38B 2,541B EV / Sales 2026 *
6.22x
EV / Sales 2027 * 5.25x
Free-Float
98.13%
Yield 2026 *
-
Yield 2027 * -
1 day-1.20%
1 week-0.82%
Current month-0.56%
1 month+9.82%
3 months+34.66%
6 months+37.64%
Current year+57.43%
1 week 68.7
Extreme 68.7
72.14
1 month 61.67
Extreme 61.67
73.69
Current year 39.71
Extreme 39.71
73.69
1 year 39.71
Extreme 39.71
73.69
3 years 19.2
Extreme 19.2
73.69
5 years 14.87
Extreme 14.87
73.69
10 years 13.42
Extreme 13.42
73.69
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-3,925 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%-0.82%+65.67%+225.01% 16.84B
-2.69%-0.48%+53.97%+66.82% 66.33B
-0.92%+7.67%+12.64%+93.22% 60.62B
0.00%+0.39%+22.34%+89.58% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
-2.32%-2.24%+76.50%+56.02% 32.22B
+2.62%+5.90%-37.29%+386.59% 26.58B
Average -0.67%-0.04%+39.68%+181.41% 42B
Weighted average by Cap. -0.84%+0.16%+37.78%+155.13%

Financials

2026 *2027 *
Net sales 2.56B 2.32B 2.14B 1.93B 3.64B 241B 3.77B 25.73B 10.2B 129B 9.59B 9.39B 409B 2.88B 2.61B 2.41B 2.18B 4.1B 271B 4.24B 28.96B 11.48B 145B 10.79B 10.57B 460B
Net income 895M 811M 750M 677M 1.28B 84.39B 1.32B 9.01B 3.57B 45.08B 3.36B 3.29B 143B 1.02B 926M 856M 772M 1.46B 96.31B 1.51B 10.28B 4.08B 51.45B 3.83B 3.75B 163B
Net Debt -943M -855M -791M -713M -1.34B -88.94B -1.39B -9.5B -3.77B -47.51B -3.54B -3.46B -151B -1.74B -1.58B -1.46B -1.32B -2.48B -164B -2.57B -17.53B -6.95B -87.69B -6.53B -6.4B -278B
Projected Income Statement - Annual - Exelixis, Inc.
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-11-13 $69.00 -1.20% 1,522,005
26-11-12 $69.84 -1.22% 1,631,824
26-11-11 $70.70 +0.17% 2,230,034
26-11-10 $70.58 -1.62% 5,583,516
26-11-09 $71.74 +3.12% 4,826,248
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Exelixis, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
69.00USD
Average target price
61.57USD
Spread / Average Target
-10.77%
  1. Stock Market
  2. Stocks
  3. EXEL Stock